Amneal Pharmaceuticals and VantAI have joined the ranks of companies to decide that a new year demands a new look, each unveiling fresh branding this week, aligned with their respective plans for 2026.
VantAI has undergone the more fundamental of the two changes, rebranding as Proxima in conjunction with an $80 million seed financing round. The company’s original name combined the “vant” common to most Roivant businesses with the “AI” derived from its focus on artificial intelligence.
Proxima said it chose its new name to reflect “its singular focus on building out both the technology and data layer needed to unlock proximity-based therapeutics.”
As VantAI, the company already worked on ways to understand and target protein-protein interactions. The new name makes that focus part of the branding ahead of a push to use the $80 million round to develop proximity-modulating therapeutics.
Unlike VantAI, Amneal has kept its name, focusing its changes instead on its visual identity. The company, which sells generics and specialty medicines, has adopted a new black-and-yellow color scheme and a signature-style logo to reinforce “its purpose of reimagining what’s possible to make medicine accessible for all.”
The new logo features the word “Amneal” in a handwritten style, displayed alternately in yellow script on a black background and vice versa on the company’s website. Amneal said the new logo is “inspired by the act of prescribing, symbolizing the trust placed in healthcare providers and the real-world impact each prescription has on patients.”
“As Amneal has grown and diversified, our brand needed to evolve with us,” co-CEO Chirag Patel said in this week's announcement unveiling the makeover. “This new brand reflects who we are today and where we are headed. It signals our ambition, our capabilities, and our unwavering focus on expanding access to medicines that make a meaningful difference in people’s lives.”
While discussing Amneal’s strategy at the 2026 J.P. Morgan Healthcare Conference Tuesday, Patel didn’t mention the rebrand directly, but the company’s “make medicine accessible for all” mantra ran through the executive’s comments. For example, when an analyst asked about Amneal’s generics business, Patel corrected him jovially, saying, “affordable medicines, sorry—if you can use that term, [it] would be great.”